TAM August 2024 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
August 2024, Volume 32, Issue 4
Overview
- CME Credit Available: 6.0 AMA PRA Category 1 Credits™
- Release Date: August 12, 2024
- Expiration Date: August 12, 2025
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 3 articles, the learner will be better able to describe and utilize the important new data presented at the 2024 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of:
- Neuropsychiatric complications in people with HIV, including cardiovascular disease, cancer, obesity, and frailty
- SARS-CoV-2, including long COVID and its clinical manifestations
- Management of long-acting injectable antiretroviral therapy for patients with HIV, including adherence challenges
- Hepatitis B, C, and D epidemiology and treatment
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from August 12, 2024, to August 12, 2025. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Contributors
Dr Corley reported no relevant financial relationships with ineligible companies. (Updated June 6, 2024)
Dr Letendre reported grant funding paid to his institution from Merck & Co, Inc. (Updated June 5, 2024)
Dr Nightingale reported no relevant financial relationships with ineligible companies. (Updated June 6, 2024)
Dr Antar reported no relevant financial relationships with ineligible companies. (Updated May 31, 2024)
Dr Peluso reported consulting income from Astra-Zeneca, Gilead Sciences, Inc, and Apellis Pharmaceuticals, and research support from Aerium Therapeutics and Shionogi. (Updated June 9, 2024)
Dr Gunaratne reported no relevant financial relationships with ineligible companies. (Updated July 18, 2024)
Dr Zucker reported no relevant financial relationships with ineligible companies. (Updated July 18, 2024)
Dr Tieu reported grant support from GSK and Shionogi. (Updated July 18, 2024)
Dr Wilkin reported serving as a consultant to ViiV Healthcare and Merck and Co, Inc; grants/grants pending to his institution from Merck and Co, Inc. (Updated July 18, 2024)
Dr Taylor reported no relevant relevant financial relationships with ineligible companies. (Updated July 18, 2024)
Planners/Reviewers
Reviewer 1 reported consulting or advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and Gilead Sciences, Inc. (Updated March 6, 2024)
Reviewers 2 and 3 reported no relevant financial relationships with ineligible companies. (Updated June 28, 2024)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and Gilead Sciences, Inc. (Updated March 6, 2024)
Dr Benson reported grants/grants pending awarded to her institution from DNAe Group Holdings, Ltd, and Gilead Sciences, Inc.; consulting or advisor fees from NDA Partners, LLC. (Updated March 6, 2024)
Dr Hirsch reported no relevant financial relationships with ineligible companies. (Updated March 6, 2024)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of the contributors and do not necessarily represent the opinions or recommendations of the IAS–USA.
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.